Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07583251 · ClinicalTrials.gov registry record · Phase 1
Safety And Tolerability Of Gamma Glutamylcysteine (GGC) Oral Supplementation In MCI Patients
A Phase 1 study, sponsored by Pravat Mandal.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 9
- Enrollment target
NCT07583251: Recruiting Phase 1 study, sponsored by Pravat Mandal.
NCT07583251 is a Phase 1 study that is actively recruiting participants, run by Pravat Mandal. The registered enrollment target is 9 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (85% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07583251, a Phase 1 study, is actively recruiting participants, sponsored by Pravat Mandal.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 9 participants
- Enrollment target
Study Summary
The goal of this study is to evaluate the safety and tolerability of Gamma Glutamylcysteine (GGC) supplement at different doses (400mg/day or 800mg/day or 1200mg/day) when administered orally to patients with MCI over 3 months. This study is designed to generate preliminary clinical safety data to inform the feasibility and design of larger controlled trials.
Primary Outcome
Safety: Creatinine not more than 1.5mg/dL, AST and ALT levels not more than 1.5 X ULN.
Interventions
- DRUG Gamma- Glutamylcysteine
- DRUG Gamma- Glutamylcusteine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 9 participants |
| Start Date | 2026-06 |
| Est. Completion | 2027-02 |
| Phase | Phase 1 |
What NCT07583251 shows while recruiting
NCT07583251 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 9 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (85% lower).
The record links to 0 conditions, and to 2 interventions - of which Gamma- Glutamylcysteine is the first listed.
NCT07583251 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT07583251 about?
NCT07583251 is a clinical study titled "Safety And Tolerability Of Gamma Glutamylcysteine (GGC) Oral Supplementation In MCI Patients". The goal of this study is to evaluate the safety and tolerability of Gamma Glutamylcysteine (GGC) supplement at different doses (400mg/day or 800mg/day or 1200mg/day) when administered orally to patients with MCI over 3 months. This study is designed to generate preliminary clinical safety data to i...
What is the current status of trial NCT07583251?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 9 participants. The study started on 2026-06. Estimated completion is 2027-02.
What interventions are being tested in trial NCT07583251?
The interventions under investigation include: Gamma- Glutamylcysteine (DRUG), Gamma- Glutamylcusteine (DRUG).
Who is sponsoring clinical trial NCT07583251?
This trial is sponsored by Pravat Mandal, which has 3 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT07583251's enrollment target sits among peer trials
9 1955th of 2000 higher than 42 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia